# Omid Hamid

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/omid-hamid/

## Facts

| Field | Value |
| --- | --- |
| Citations | 85,135 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 98 |
| i10-index | 317 |
| Last Known Institution | Cedars-Sinai Medical Center |
| OpenAlex ID | https://openalex.org/A5028592995 |
| ORCID iD | https://orcid.org/0000-0002-8238-4655 |
| Works | 889 |

## Researcher papers

- [Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer](https://scholariq.org/papers/safety-and-activity-of-anti-pd-l1-antibody-in-patients-with-advanced-cancer/)
- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study](https://scholariq.org/papers/epacadostat-plus-pembrolizumab-versus-placebo-plus-pembrolizumab-in-patients/)
- [Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/overall-survival-benefit-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study](https://scholariq.org/papers/efficacy-and-safety-of-lifileucel-a-one-time-autologous-tumor-infiltrating/)
- [Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/three-year-overall-survival-with-tebentafusp-in-metastatic-uveal-melanoma/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)

## Researcher university

- [Cedars-Sinai Medical Center](https://scholariq.org/institutions/cedars-sinai-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.